Clinically, ALRN-6924 is being evaluated as a monotherapy and in combination with cytarabine in patients with hematological malignancies (NCT02909972) and has entered a Phase I/II clinical trial in patients with advanced solid tumors or with preserved wild-type p53 lymphoma (NCT02264613). Here, TP53 is linked to hematologic disorder.